Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clomipramine for Post COVID-19 Condition (Long COVID)
jRCTs031230470Recruiting
- Sponsor
- Psychiatric and Neurological Disorders Research and Development Fund
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of clomipramine in post-COVID syndrome, sponsored by Psychiatric and Neurological Disorders Research and Development Fund. Primary endpoint: Safety of clomipramine. Started Sep 2024; status: recruiting.
02
Drugs
clomipramine
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on jRCTs031230470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230470.